Uptake and outcomes of small intestinal and urinary tract cancer surveillance in Lynch syndrome

Table 4 Characteristics of individuals with Lynch syndrome who chose to undergo and/or completed urinary tract cancer surveillance

	Surveillance chosen (n = 58)	Surveillance not chosen(n = 97)	P value	Surveillance completed (n = 32)	Surveillance not completed (n = 26)	P value
Age (yr), median (IQR)	48 (39-60)	40 (32-55)	0.018a	45 (40-61)	50 (37-60)	0.772
Female	37 (64%)	63 (65%)	0.884	26 (81%)	11 (42%)	0.002a
Race			0.431			0.498
White	54 (93%)	85 (88%)		30 (94%)	24 (92%)
Black	1 (2%)	2 (2%)		0 (0%)	1 (4%)
Asian	3 (5%)	4 (4%)		2 (6%)	1 (4%)
Other	0 (0%)	2 (2%)		-	-
Unknown	0 (0%)	4 (4%)		-	-
Hispanic ethnicity	0 (0%)	2 (2%)	0.336	-	-	-
AJ ancestry	3 (5%)	13 (13%)	0.229	3 (9%)	0 (0%)	0.006a
Lynch syndrome gene			0.640			0.171
MLH1	8 (14%)	21 (22%)		3 (9%)	5 (19%)
MSH2 or EPCAM	17 (29%)	23 (24%)		9 (28%)	8 (31%)
MSH6	17 (29%)	28 (29%)		13 (41%)	4 (15%)
PMS2	16 (28%)	25 (26%)		7 (22%)	9 (35%)
Personal history of cancer	29 (50%)	41 (42%)	0.349	17 (53%)	12 (46 %)	0.597
Family history of UTC	15 (26%)	20 (21%)	0.477	11 (34%)	4 (15%)	0.118
Insurance			0.631			0.402
Private	50 (86%)	84 (87%)		29 (91%)	21 (81%)
Medicare	7 (12%)	9 (9%)		3 (9%)	4 (15%)
Medicaid	1 (2%)	4 (4%)		0 (0%)	1 (4%)
Provider
Provider 1	36 (62%)	85 (88%)	0.001a	28 (88%)	8 (31%)	0.000 a
Provider 2	12 (21%)	5 (5%)		2 (6%)	10 (38%)
Provider 3	10 (17%)	7 (7%)		2 (6%)	8 (31%)

^aP < 0.05. UTC: Urinary tract cancer; AJ: Ashkenazi Jewish.